FRACTYL HEALTH INC. - COMMON STOCK

1,1650

13-марта-25 14:55:42

15 мин. задержка

Акции

-0,1900

-14,02%

Сегодняшний диапазон

1,1600 - 1,3700

ISIN

N/A

Источник

NASDAQ

Fractyl Health Presents New Preclinical Data on Sustained Weight Maintenance and Improved Body Composition from its Rejuva® Single-Administration GLP-1 Pancreatic Gene Therapy in President’s Select Oral Presentation at the American Diabetes Association’s 84th Scientific Sessions

23 июн 2024 13:30:00 Источник Nasdaq GlobeNewswire
Fractyl Health to Present New Preclinical Obesity Data from Rejuva® Platform at the American Diabetes Association’s 84th Scientific Sessions

29 май 2024 07:00:00 Источник Nasdaq GlobeNewswire
Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva® at Digestive Disease Week 2024

20 май 2024 06:00:00 Источник Nasdaq GlobeNewswire
Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates

13 май 2024 16:00:00 Источник Nasdaq GlobeNewswire
Fractyl Health Presents Clinical Update on Revita® German Real-World Registry for Patients With Advanced Type 2 Diabetes (T2D)

13 май 2024 06:00:00 Источник Nasdaq GlobeNewswire
Fractyl Health to Present at BofA Securities 2024 Health Care Conference

08 май 2024 06:00:00 Источник Nasdaq GlobeNewswire
Fractyl Health to Report First Quarter 2024 Financial Results and Provide Business Updates on May 13, 2024

07 май 2024 06:00:00 Источник Nasdaq GlobeNewswire
Fractyl Health Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference and the German Diabetes Association (DDG) Annual Meeting

30 апр 2024 08:38:00 Источник Nasdaq GlobeNewswire
Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes

02 апр 2024 08:00:00 Источник Nasdaq GlobeNewswire
Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

01 апр 2024 07:00:00 Источник Nasdaq GlobeNewswire
Fractyl Health Receives FDA IDE Approval for the Revita® Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs

01 апр 2024 06:00:00 Источник Nasdaq GlobeNewswire
UPDATE -- Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity

12 мар 2024 14:06:28 Источник Nasdaq GlobeNewswire
Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity

12 мар 2024 08:38:26 Источник Nasdaq GlobeNewswire
Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita® Pivotal Clinical Trials

20 фев 2024 08:38:00 Источник Nasdaq GlobeNewswire

<<
<
1
2
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.